- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT02175849
Intensifying Multi-Drug Resistant Tuberculosis Contact Tracing by Social Network Analysis (SNAP)
Contact Tracing by Social Network Analysis to Enhance Multi-Drug Resistant Tuberculosis Case Finding in Hanoi, Vietnam
Tuberculosis burden in Vietnam increasing with contribution from low detection rates and increased drug resistance. There is a need to identify MDR-TB (MultiDrug Resistant Tuberculosis) among both notified TB cases and their contacts in the community. Traditional contact tracing often focuses on household contacts while strains of TB circulate in homes, schools, workplaces, and beyond. Social network Analysis (SNA) is a comprehensive approach which includes a set of persons and the connections among them used for analysis of structure of disease transmission.
In this study, SNA will be used to collect network data from 60 newly detected Rifampicin resistant TB patients including an expected 50 MDR-TB patients living in Hanoi, and to identify and test potential MDR-TB cases.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
The study will identify and recruit 60 newly detected Rifampicin resistant TB patients including an expected 50 MDR-TB patients living in Hanoi (index cases) who will undergo SNA of contacts and places they have stayed during 3 months preceding their TB diagnosis including residence, travel history, places of social aggregation in relation with their risk behaviour.
Patients will be interviewed to investigate contacts before the confirmation of MDR-TB (for early contact detection and minimize the risk of information lost due to patient default during treatment). Data analysis will focus on MDR-TB social networks using Cytoscape software.
After the first two enrolled Rifampicin resistant MDR-TB cases, social network data will be analyzed to identify close contacts, mutual contacts, mutual places and high risk locations. The Social Network Questionnaire (SNQ) will be contextualized to the Vietnamese setting and validated in a pilot study. Eligible contacts and locations will undergo MDR-TB screening.
Approximately 720 contacts will undergo active screening (on 2 occasions per individual: at the time of contact identification and 6 months later). Contacts will include household contacts, close contacts, mutual contacts and symptomatic individuals with significant exposure to the index case at mutual locations within a closed environment.
Contact screening will involve clinical assessment, chest X-ray and sputum or gastric aspirate collection for TB culture, molecular techniques and microbiological identification.
If contacts are screened and detected as having Rifampicin resistant TB, they will be invited to be included in SNA for further analysis.
The number of MDR-TB detected by SNA will determine whether transmission of MDR-TB not otherwise detected by routine contact investigation (only household contact tracing) is important. While traditional contact tracing practices in Vietnam mainly focus on household contacts to detect secondary cases of TB, this SNA is expected not only to identify secondary cases of MDR-TB within an extended catchment but to also identify the source cases of MDR-TB patients to " turn off the tap" of MDR-TB transmission. Moreover, the places identified as the sources of sustained transmission will be targeted for case finding along with appropriate resource allocation.
In this study analysis will focus on the costs of contact tracing with Social Network Questionnaires, the proportion of MDR-TB among eligible contacts by subgroup, the proportion of MDR-TB among Rifampicin resistant TB patients and the genotyping pattern of MDR -TB patients.
Tipo di studio
Iscrizione (Effettivo)
Contatti e Sedi
Luoghi di studio
-
-
-
Hanoi, Vietnam, 10000
- National Lung Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- PATIENTS: Newly detected rifampicin resistant TB or MDR-TB patients living in Hanoi for at least 3 months preceding a diagnosis made between 2013-2015.
- CONTACTS: During the 3 months before the patient's TB or MDR-TB diagnosis: all persons who spend an average of >4 hours per day in the same residence as the patient AND/OR any individual who has had frequent and prolonged contact with the patient AND/OR anyone who has spent time in a closed environment with an MDR-TB patient
- PATIENTS AND CONTACTS: All ages
- PATIENTS AND CONTACTS: Living in Hanoi during the study period.
Exclusion Criteria:
-PATIENTS AND CONTACTS: Lack of informed consent for participation.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Coorte
- Prospettive temporali: Prospettiva
Coorti e interventi
Gruppo / Coorte |
|---|
|
Drug resistant TB patients
Patients with rifampicin resistant TB or MDR-TB newly confirmed by drug susceptibility tests (DST)
|
|
Contacts
Contacts of patients with newly detected rifampicin resistant TB or MDR-TB in households, schools, workplaces and other locations.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Yield of MDR-TB case detection through SNA
Lasso di tempo: Six months
|
The number of MDR-TB cases notified from contacts identified by SNA and who would not have been detected by routine screening.
|
Six months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
MDR-TB incidence among subgroups of contacts
Lasso di tempo: Six months
|
The proportion of MDR-TB among eligible contacts by subgroup (household contacts, close contacts, mutual contacts, eligible contacts from mutual places with closed environment).
|
Six months
|
|
MDR-TB incidence among rifampicin resistant TB cases
Lasso di tempo: Six months
|
Incidence of MDR-TB confirmed by drug susceptibility tests (DST) among rifampicin resistant TB patients.
|
Six months
|
|
MDR-TB genotype
Lasso di tempo: Six months
|
Consistency or difference between TB genotype of enrolled MDR-TB patients and contacts/secondary cases.
|
Six months
|
|
Cost-effectiveness ratio of SNA and passive case finding strategies
Lasso di tempo: Six months
|
The incremental cost-effectiveness ratio (ICERs) between SNA and passive case finding for one MDR-TB case detected (i.e, the cost of SNA minus the cost of passive case finding divided by the yield in terms of case detection of SNA minus the yield of passive CF)
|
Six months
|
Collaboratori e investigatori
Collaboratori
Pubblicazioni e link utili
Collegamenti utili
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 10TB
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezione da tubercolosi
-
François SpertiniUniversity of OxfordCompletatoTubercolosi | Mycobacterium tuberculosis, protezione controSvizzera
-
Assistance Publique - Hôpitaux de ParisCompletatoInfezione ossea e osteoarticolare dovuta a ceppi MDR M. TuberculosisFrancia
-
Serum Institute of India Pvt. Ltd.Vakzine Projekt Management GmbHCompletatoInfezione da Mycobacterium TuberculosisGabon, Kenya, Sud Africa, Tanzania, Uganda
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); WalimuReclutamentoTubercolosi, Polmonare | Infezione da Mycobacterium TuberculosisUganda
-
Global Alliance for TB Drug DevelopmentCompletatoTubercolosi | Tubercolosi, Polmonare | Malattia polmonare | Tubercolosi multiresistente ai farmaci | Tubercolosi sensibile ai farmaci | Tubercolosi resistente ai farmaci | Infezione da Mycobacterium TuberculosisStati Uniti
-
Global Alliance for TB Drug DevelopmentCompletatoTubercolosi | Tubercolosi, Polmonare | Malattia polmonare | Tubercolosi multiresistente ai farmaci | Tubercolosi sensibile ai farmaci | Tubercolosi resistente ai farmaci | Infezione da Mycobacterium TuberculosisStati Uniti